https://www.selleckchem.com/products/sbe-b-cd.html
Time to confirmed disability at three months or changes in composite MSFC are reasonable primary outcome measures to use in future SPMS trials with a suggestion that the MSFC may be more sensitive to progressive disease changes. PROs and MRI measures following brain parenchymal volume are reasonable secondary outcome measures to incorporate into future phase III trials in SPMS. Some successful trials may have been related to patient selection for less inflammatory disease, which confounds the comparison between successful trials. Time
Like
Comment
Share
